Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [¹⁸F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression.

ABSTRACT: Despite the anti-proliferative and survival benefits from tumor treating fields (TTFields) in human glioblastoma (hGBM), little is known about the effects of this form of alternating electric fields therapy on the aberrant glycolysis of hGBM. [¹⁸F]FDG is the most common radiotracer in cancer metabolic imaging, but its utility in hGBM is impaired due to high glucose uptake in normal brain tissue. With TTFields, radiochemistry, Western blot, and immunofluorescence microscopy, we identified pyruvate kinase M2 (PKM2) as a biomarker of hGBM response to therapeutic TTFields. We used [¹⁸F]DASA-23, a novel radiotracer that measures PKM2 expression and which has been shown to be safe in humans, to detect a shift away from hGBM aberrant glycolysis in response to TTFields. Compa

SUBMITTER: Patel CB 

PROVIDER: S-EPMC7689378 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature